Moderna, Inc.’s emergency use authorization request for its COVID-19 vaccine in children younger than 6 years could be the first major test of the US Food and Drug Administration’s – and its external advisors’ – comfort with a vaccine that falls at or below the 50% clinical efficacy threshold.
On 28 April, Moderna announced submission of an EUA request for mRNA-1273 in two groups of children: ages 6 months-<2...







